Compare
Erasca, Inc. vs Nkarta, Inc. vs Dianthus Therapeutics, Inc. vs Annexon, Inc.
| Latest fiscal year | Erasca, Inc. ERAS | Nkarta, Inc. NKTX | Dianthus Therapeutics, Inc. DNTH | Annexon, Inc. ANNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $2.04M | n/a |
| Revenue growth (YoY) | n/a | n/a | -67.3% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | n/a |
| Net margin | n/a | n/a | n/m | n/a |
| Net income | -$124.55M | -$104.08M | -$162.34M | -$206.69M |
| EPS (Diluted) | -$0.44 | -$1.41 | -$4.20 | -$1.34 |
| Operating cash flow | -$95.45M | -$88.70M | -$129.06M | -$186.36M |
| Free cash flow | -$95.58M | -$89.91M | n/a | -$186.49M |
| Cash & equivalents | $73.81M | $39.63M | $51.09M | $162.05M |
| Total assets | $396.15M | $404.21M | $530.92M | $277.57M |
| Total liabilities | $70.98M | $91.88M | $37.52M | $65.92M |
| Shareholders' equity | $325.17M | $312.32M | $493.40M | $211.65M |
| Return on year-end equity | -38.3% | -33.3% | -32.9% | -97.7% |
| Shares outstanding | 284.16M | 71.08M | 43.22M | 149.36M |
Revenue, most recent five fiscal years
| Fiscal year | Erasca, Inc. | Nkarta, Inc. | Dianthus Therapeutics, Inc. | Annexon, Inc. |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $2.04M Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $6.24M Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | n/a | $2.83M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | n/a | n/a |
| 4 years earlier | n/a | n/a | n/a | n/a |